Search Within

Arielle Elkrief

Formats
  1. Journal Article (24)
  2. Meeting Abstract (14)
  3. Editorial (2)
  4. Review (2)
  5. Correspondence (1)
Groups
  1. GME, Medicine (43)
  2. Graduate Medical Education (43)
  3. Sloan Kettering Institute Postdocs (43)
  4. Department of Medicine (37)
  5. Solid Tumor Oncology Division (37)
  6. Thoracic Oncology (34)

More Groups

People
  1. Adam Schoenfeld (28)
  2. Marc Ladanyi (20)
  3. Matthew Hellmann (11)
  4. Charles Rudin (10)
  5. Gregory Riely (9)
  6. Hira Rizvi (9)

More People

Years
  1. 2025 (7)
  2. 2024 (10)
  3. 2023 (17)
  4. 2022 (7)
  5. 2021 (2)
Publications
  1. Journal of Thoracic Oncology (10)
  2. Journal of Clinical Oncology (9)
  3. Clinical Cancer Research (4)
  4. JCO Precision Oncology (4)
  5. Annals of Oncology (3)
  6. Journal for ImmunoTherapy of Cancer (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (13)
  2. Elsevier Inc. (11)
  3. American Association for Cancer Research (5)
  4. Oxford University Press (4)
  5. Biomed Central Ltd (2)
  6. Nature Publishing Group (2)

More Publishers

Results (43)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Factors associated with disease progression after discontinuation of immunotherapy for immune-related toxicity in non-small cell lung cancer
    Meeting Abstract

    Pecci, F.; Thummalapalli, R.; Alden, S.; Ricciuti, B.; Alessi, J. V.; Elkrief, A.; Rizvi, H.; Wang, X.; Egger, J. V.; Vaz, V. R.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Three-year outcomes with first-line pembrolizumab, in patients with non-small-cell lung cancer and a PD-L1 tumor proportion score >90%
    Meeting Abstract

    Ricciuti, B.; Arielle Elkrief, A.; Lin, J.; Altan, M.; Alessi, J.; Gandhi, M.; Pecci, F.; Lamberti, G.; Di Federico, A.; Wang, X.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Impact of aneuploidy and chromosome 9p loss on tumor immune microenvironment and immune checkpoint inhibitor efficacy in NSCLC
    Journal Article

    Alessi, J. V.; Wang, X.; Elkrief, A.; Ricciuti, B.; Li, Y. Y.; Gupta, H.; Spurr, L. F.; Rizvi, H.; Luo, J.; Pecci, F.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Clinical and genomic landscape of EGFR -mutant lung cancers (LCs) with squamous and adenosquamous differentiation
    Meeting Abstract

    Elkrief, A.; Falcon, C. J.; Richards, A. L.; Dymun, A.; Paik, P. K.; Aly, R. G.; Rekhtman, N.; Rudin, C. M.; Quintanal-Villalonga, A.; Yu, H. A.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Perioperative immunochemotherapy (mDCF + avelumab) in locally advanced gastro-esophageal adenocarcinoma: A phase II trial
    Meeting Abstract

    Alcindor, T.; Fiset, P. O.; Opu, T.; Dehghani, M.; Bertos, N.; Mueller, C. L.; Cools-Lartigue, J.; Hickeson, M.; Marcus, V.; Camilleri-Broët, S.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Clinical activity of mitogen-activated protein kinase (MAPK) inhibitors in patients with MAP2K1 (MEK1)-mutated metastatic cancers: A systematic review and meta-analysis
    Meeting Abstract

    Dankner, M.; Petrecca, S.; Fabi, F.; Nowakowski, A.; Rajadurai, C. V.; Rousselle, E.; Stein, A.; Bian, D. J.; Tai, P.; Belaiche, A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Fecal microbiota transplantation for refractory immune-checkpoint-inhibitor colitis
    Meeting Abstract

    Elkrief, A.; Nicholas, W.; Smith, N.; Dai, A.; Slingerland, J. B.; Aleynick, N.; Lumish, M. A.; Giardina, P.; Chaft, J. E.; Chapman, P. B.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Clinicopathologic, genomic, and immunophenotypic landscape of ATM mutations in non-small cell lung cancer
    Journal Article

    Ricciuti, B.; Elkrief, A.; Alessi, J.; Wang, X.; Li, Y.; Gupta, H.; Muldoon, D. M.; Bertram, A. A.; Pecci, F.; Lamberti, G.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Combination therapy with MDM2 and MEK inhibitors is effective in patient-derived models of lung adenocarcinoma with concurrent oncogenic drivers and MDM2 amplification
    Journal Article

    Elkrief, A.; Odintsov, I.; Markov, V.; Caeser, R.; Sobczuk, P.; Tischfield, S. E.; Bhanot, U.; Vanderbilt, C. M.; Cheng, E. H.; Drilon, A.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: A cohort study
    Journal Article

    Elkrief, A.; Alessi, J. M. V.; Ricciuti, B.; Brown, S.; Rizvi, H.; Preeshagul, I. R.; Wang, X.; Pecci, F.; Di Federico, A.; Lamberti, G.; more...
    Journal for ImmunoTherapy of Cancer (2023)

    Fulltext@MSK | Save